Moreover, TFAP2A inhibition resulted in elevated TG levels and reduced FFA levels in NSCLC cells, which could also be reversed by CES3 overexpression (Figure 6B and 6C). The gene discussed is CES3; the disease is non-small cell lung carcinoma.